Search alternatives:
somatic decrease » small decrease (Expand Search)
dramatic » aromatic (Expand Search)
Showing 461 - 480 results of 487 for search '((dramatic decrease) OR (somatic decrease))', query time: 0.23s Refine Results
  1. 461
    Image 6_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 6_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  2. 462
    Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  3. 463
    Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  4. 464
    Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  5. 465
    Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  6. 466
    Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  7. 467
    Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1

    Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1 by Liaozhang Wu (8371008)

    Published 2025
    “…Mitophagy inhibitor Mdivi-1 reversed the induction of ferroptosis effects of diquat via decreased Fe2+ content and increased Ca2+ level. knockdown of METTL14 reversed the therapeutic effect of Eda on diquat-induced injury. …”
    Save to List
    Saved in:
  8. 468
    Image 4_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 4_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  9. 469
    Image 8_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 8_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  10. 470
    Image 10_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 10_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  11. 471
    Image 2_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 2_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  12. 472
    Table13_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table13_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  13. 473
    Table6_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table6_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  14. 474
    Table4_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table4_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  15. 475
    Table8_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table8_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  16. 476
    Table12_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table12_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  17. 477
    Table3_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xlsx

    Table3_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xlsx by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  18. 478
    Table10_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table10_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  19. 479
    Table9_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table9_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  20. 480
    Table1_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table1_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:

Search Tools: